earningsconfidence high
Protara Therapeutics Reports Q1 2026 Results, Advances TARA-002 Programs in LMs and NMIBC
Protara Therapeutics, Inc.
2026-Q1 EPS reported
-$0.31
- Cash and cash equivalents and investments of $177.4 million as of March 31, 2026, expected to fund operations into 2028.
- Net loss of $17.8 million ($0.31 per share) for Q1 2026, compared to $11.9 million loss in Q1 2025.
- Intends to submit BLA for TARA-002 in Lymphatic Malformations in second half of 2027 based on STARBORN-1 trial.
- Expects to complete enrollment of BCG-Unresponsive cohort in ADVANCED-2 trial and initiate ADVANCED-3 trial in BCG-Naïve patients in second half of 2026.
- Updated interim safety and durability data from STARBORN-1 to be presented at ISSVA World Congress in May 2026.
item 2.02item 9.01
This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.